Track topics on Twitter Track topics that are important to you
Amyotrophic Lateral Sclerosis: Opportunity Analysis and Forecast to 2027SummaryAmyotrophic Lateral Sclerosis ALS is a motor neuron degenerative disease which affects both upper motor neurons UMN and lower motor neurons LMN. It is a progressive disease, with patients becoming increasingly dependent on carers and physicians as time from onset increases, and ultimately, it is fatal. ALS can be split ...
AU $3.00End Date: Tuesday Dec-25-2018 9:10:57 ESTBuy It Now for only: AU $3.00Buy It Now | Add to watch list Biotech365 : 1947 SILVER THREEPENCE PREDECIMAL COIN NICE AVERAGE CIRCULATED #VWR80 BioMarketplace You want to propose your products or a … Continue reading →
NewsAltered peptides from a South American wasp's venom can kill bacteria but are nontoxic to human cells.Contributed Author:
Opinion: Patent abuse by drug makers is one of the most influential drivers of rising drug prices. https://buff.ly/2L1VEpe
NewsThe report found a minimal increase in prescription drug spending, the slowest increase in drug costs since 2012.Contributed Author:
Newly empowered Democrats in D.C. are hunting for bigger and bolder ways to lower drug prices and taking aim at the patents held by drug makers.
NewsResearchers are having difficulty studying the medical potential of marijuana because of the drug's classification.Contributed Author:
While a positive step for Roche's I/O ambitions, it will likely run into trouble differentiating Tecentriq from the first-line regimen of Keytruda plus chemo.
Patent abuse is forcing agonized patients to struggle to afford treatment, ration their medicines, and absorb the cost of high drug prices with bodies.
In November 2018, Indian generics maker Glenmark Pharmaceuticals (Glenmark) announced the approval of generics for the treatment of multiple sclerosis (MS) and pneumonia.
In the National Institute for Health and Care Excellence’s (NICE) guideline NG5 — ‘Medicines optimisation: the safe and effective use of medicines to enable the best possible outcomes’ — sit recommendations around patient decision aids (PDAs) used in consultations involving ...
Annual Meeting adjourned solely with respect to Proposal 4 – approval of an amendment to the Company’s Amended Certificate of Incorporation to continue to restrict certain transfers of its common stock in order to preserve the tax treatment of its … Continue reading →
Late Thursday Genentech said the U.S. Food and Drug Administration (FDA) granted regulatory approval for a combination of Tecentriq and Avastin for treatment of some metastatic non-squamous non-small cell lung cancer (NSCLC) patient.
Roche's lung cancer combo treatment wins FDA approval https://reut.rs/2RAIPol
The FDA is amending its label for alemtuzumab, a drug used to treat multiple sclerosis (MS) and leukemia, after 13 patients reported cases of ischemic stroke, hemorrhagic stroke or arterial dissection related to use of the medication.
John O’Brien has been named as senior advisor to HHS Secretary Alex Azar for drug pricing reform, the agency announced Dec. 6.
Edison Investment Research - Pharmaceutical & healthcare - Elbit Medical Technologies: Elbit Medical Technologies’ two portfolio investments continue to advance. Notably, Gamida Cell announced a $53m IPO on Nasdaq in late October and presented NiCord data at the American Society of Hematology (ASH) annual meeting in December. InSightec reported record revenues for Q318 and received FDA appro...
Ultragenyx Pharmaceutical (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, Kyowa Hakko Kirin and Kyowa Kirin International today announced that Crysvita™ (burosumab injection) has been approved by Health Canada for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of a...
A ruling could chill deals that small drug makers may pursue in hopes of finding larger partners to get their medicines to market.
Time for another look at AbbVie’s work on Rova-T (an antibody-drug conjugate targeting the tumor antigen DLL3), and for some hard thoughts about what drug development is really like. The last time I wrote about this program, things didn’t look good. Now they look even worse. A Phase III trial of the drug has been
$RARE and Kyowa Kirin Announce Health Canada Approval of Crysvita™ for the Treatment of XLH in Adults and Children https://globenewswire.com/news-release/2018/12/06/1663089/0/en/Ultragenyx-and-Kyowa-Kirin-Announce-Health-Canada-Approval-of-Crysvita-buro
$RARE and Kyowa Kirin Announce Health Canada Approval of Crysvita™ for the Treatment of XLH in Adults and Children https://globenewswire.com/news-release/2018/12/06/1663089/0/en/Ultragenyx-and-Kyowa-Kirin-Announce-Health-Canada-Approval-of-Crysvita-burosumab-injection-for-the-Treatment-of-X-linked-Hypophosphatemia-XLH-in-Adults-and-Children.html …
1. Researchers have identified a significant increase in hospitalizations due to infective endocarditis related to drug use. 2. Heart valve surgeries among patients with drug use-associated infective endocarditis have also increased with the opioid epidemic. Evidence Rating Level: 2 (Good) Study Rundown: The authors of this study utilized a statewide hospital discharge database to examine […...